Frédéric Joliot Institute for Life Sciences - On the same theme

Cyanine 5-huwentoxin-IV : a new imaging agent for non-small cell lung cancer ?

Mon, 10 Nov 2025 11:00:00 GMT

A team from SIMoS (DMTS) has demonstrated the ability of a peptide derived from a spider venom toxin to detect overexpressed sodium channels in a metastatic non-small cell lung cancer (NSCLC) cell line.

Llama antibodies: new therapeutic avenues against schizophrenia

Wed, 10 Sep 2025 10:00:00 GMT

Researchers from SIMoS (DMTS) contributed to the characterization of a nanobody (VHH) designed by scientists at the Institut de Génomique Fonctionnelle in Montpellier. They performed tritium labeling and biodistribution tracking of this VHH, which can specifically activate a glutamate receptor involved in schizophrenia. This work was published in Nature.

Unprecedented method for high-yield production of monoclonal antibodies through targeted cell fusion

Fri, 05 Sep 2025 10:00:00 GMT

Researchers at SPI (DMTS) have developed a high-yield strategy for producing monoclonal antibodies by preselecting the antibody-producing cells most likely to form viable hybridomas. This represents a step towards a wider use of this technology which should help to further reduce the number of animals to be immunised.

Une méthode d’analyse en IRM de diffusion pour étudier les altérations des faisceaux de substance blanche dans la maladie d’Alzheimer et la pathologie LATE ?

Wed, 11 Jun 2025 10:00:00 GMT

Des chercheurs du SHFJ, de NeuroSpin et du GHU Paris Psychiatrie & Neurosciences mettent en évidence des différences dans les altérations des faisceaux de substance blanche entre des patients diagnostiqués Alzheimer et d’autres vraisemblablement atteints de la pathologie LATE.

A new toxin derived from snake venom to treat kidney diseases

Thu, 20 Mar 2025 11:00:00 GMT

Researchers at SIMoS, SPI (DMTS) and BioMaps (SHFJ) report the development of a new molecule, MQ232, derived from mambaquaretin. As a specific antagonist of the vasopressin V2 receptor, MQ232 is a promising drug candidate for the treatment of renal pathologies.

Study of subcortical neuromodulatory systems alteration in Alzheimer's disease and related disorders

Wed, 16 Oct 2024 10:00:00 GMT

A team from GHU Paris and SHFJ has used brain MRI to study the integrity of the locus coeruleus and nucleus basalis of Meynert in patients with early-onset Alzheimer's disease (AD), age-related TDP-43 encephalopathy (LATE) and fronto-temporal dementia (FTD). Both structures are altered in early AD, LATE and probably FTD, making these neuromodulatory areas potential therapeutic targets

Functionalization of the B subunit of Shiga toxin as a vaccine tool

Fri, 26 Jan 2024 11:00:00 GMT

Researchers at SIMoS (DMTS) describe the synthesis, engineering and evaluation of the properties of the B subunit of bacterial Shiga toxin (STxB), administered mucosally, as a vaccine tool. Their results confirm the value of using a synthetic STxB in an anti-tumor and anti-infectious vaccination strategy.

Click-Chemistry: optimized drug delivery from nanomicelles into tumor cells

Fri, 10 Nov 2023 11:00:00 GMT

Researchers at SCBM have used a click-and-release chemistry approach to mass-release an anti-cancer drug into cells from cleavable nanomicelles, thanks to a bioorthogonal activation process. A step towards the development of new nanomedicines

Longitudinal monitoring of tauopathy in PET imaging to better understand the various modalities of clinical evolution of Alzheimer's disease

Wed, 02 Aug 2023 10:00:00 GMT

A joint team from GHU Paris and BioMaps (SHFJ) conducted a 2-year longitudinal study of 27 people with Alzheimer's disease, tracking the progression of tau pathology measured by PET imaging, of cortical atrophy using MRI, and their links with cognitive decline.

Exploring the potential of a model cyanobacterium for the photosynthetic production of high-value terpenes

Fri, 10 Feb 2023 11:00:00 GMT

Through two publications, an I2BC team demonstrates the high biotechnological potential of the model cyanobacterium Synechocystis PCC 6803 for the photosynthetic production of high value-added organic compounds, the terpenes.

Discovery of a natural peptide from black mamba venom, with anticholinergic properties

Mon, 21 Nov 2022 11:00:00 GMT

A team from SIMoS (DMTS) identifies and characterizes a toxin isolated from black mamba venom, whose specific anticholinergic properties at the type 2 acetylcholine receptor, a regulator of arterial tone, position it as a potential drug candidate for the treatment of cardiovascular diseases.

Molecular engineering of antibodies to accommodate antigenic drift of SARS-CoV-1 and 2

Thu, 22 Sep 2022 10:00:00 GMT

Researchers from SIMoS and SPI (DMTS) demonstrate that molecular engineering of llama antibodies, capable of neutralizing SARS-CoV-1, allows to obtain optimized antibodies with very high affinities for SARS-CoV-2 and its variants, the culprits of the Covid-19 epidemic.

How to make biodrugs less immunogenic? Answer with a monoclonal antibody with anti-inflammatory properties

Mon, 20 Jun 2022 10:00:00 GMT

SIMoS team, in collaboration with Bicêtre Hospital, shows that certolizumab pegol, a pegylated monoclonal antibody fragment for anti-inflammatory use, is less likely to trigger an adverse immune response than the non-pegylated form.

Alzheimer's: PET imaging of tau protein predicts cognitive decline and progression of brain atrophy

Sun, 03 Apr 2022 10:00:00 GMT

A joint team from GHU Paris and SHFJ shows the predictive value of PET imaging data of the Tau protein in the progression of Alzheimer's disease.

7T Sodium MRI confirms early metabolic damage in Alzheimer's disease

Mon, 07 Mar 2022 11:00:00 GMT

7T Sodium MRI may well prove increasingly useful in the study of physiological processes in inflammatory and neurodegenerative diseases and brain tumors. An example is a study on Alzheimer's disease, led by a NeuroSpin team.

Deeptope: accelerating the development of therapeutic antibodies via high-throughput functional tests

Mon, 29 Nov 2021 11:00:00 GMT

Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.

PET imaging of tau and amyloid deposits improves the diagnosis of progressive amnesia

Thu, 04 Nov 2021 11:00:00 GMT

Researchers from BioMaps (SHFJ) and the Service de Neurologie de la Mémoire et du Langage (Hôpital Ste-Anne) show, through amyloid and tau molecular imaging in patients followed for 2 years, that the diagnosis of progressive amnesia in the elderly is not necessarily Alzheimer's disease and may be caused by other mechanisms clearly distinguishable from it.

Characteristics of the initial symptoms of Alzheimer's disease in young patients

Thu, 10 Jun 2021 10:00:00 GMT

Researchers from BioMaps (SHFJ) and the Department of Memory and Language Neurology (Ste Anne's Hospital) studied the early clinical signs of Alzheimer's disease (AD) reported by young patients (< 62 years old) compared to those reported in classic AD of the elderly (> 65 years old). They show that these signs are misleading and often appear in the professional context.

Synthetic biology: new tools to increase the diversity of the 2,5-diketopiperazines produced in E.coli

Fri, 25 Sep 2020 10:00:00 GMT

Researchers from I2BC (SBIGeM), in collaboration with teams from Sorbonne University, have characterized cyclodipeptide oxidases in vivo and shown that they are valuable tools for producing dehydrogenated 2,5-diketopiperazines, precursors of bioactive molecules of pharmaceutical interest, in Escherichia coli using synthetic biology approaches.

Magnetic sensors for ultra-sensitive biochips

Wed, 08 Jan 2020 11:00:00 GMT

Researchers from IRAMIS collaborated with a team from SPI (LERI) for the development of a microfluidic biochip ("lab-on-chip") based on ultra-sensitive magnetic sensors with giant magnetoresistance (GMR sensors), capable of individually and effectively detect magnetically-labeled biological targets.

A ferredoxin to fuel metabolic pathways of biotechnological interest

Mon, 14 Oct 2019 10:00:00 GMT

Researchers at BIAM and I2BC@Saclay, in collaboration with Japanese colleagues from Okayama University and Ehime, have characterized in a cyanobacterium a minor protein that diverts part of the energy from photosynthesis to secondary metabolic pathways. This discovery is promising to exploit these metabolic pathways in a biotechnological process of bioenergy production.

Alzheimer's: a more effective method to diagnose the disease?

Fri, 20 Sep 2019 10:00:00 GMT

A study conducted by Maxime Bertoux (Unit 1171 Inserm / Lille University / CHU Lille) in collaboration with researchers from the Centre Hospitalier Saint Anne, the SHFJ (CEA-Joliot), NeuroSpin (CEA-Joliot) and the ICM shows that the morphological analysis of the cortical sulci would make it possible to recognize Alzheimer's disease in 91% of the cases, against 80% now by anatomical analysis of the cortex.

"Mini-brains" for research on Alzheimer's disease

Mon, 14 Jan 2019 11:00:00 GMT

A partnership between the François Jacob Institute of Biology/CEA, The Frédéric Joliot Institute for Life Sciences/CEA and CellTechs (a Sup'Biotech lab) has led to a new approach for modeling Alzheimer's disease in vitro.

Evolution of Alzheimer's disease : a dual role of the neuroimmune reaction

Thu, 10 Jan 2019 11:00:00 GMT

A collaboration involving the Sainte-Anne Hospital, the SHFJ, the Saint-Antoine research center and the ICM identified, through a PET brain imaging study in patients with Alzheimer's disease, two distinct kinetic profiles of the cerebral neuroimmune response, that impact the disease progression differently. Researchers propose an original model of neuroinflammation, likely to open new therapeutic avenues.

An original biotechnological approach to create new bioactive molecules

Mon, 05 Mar 2018 11:00:00 GMT

Muriel Gondry's Research Team (I2BC@Saclay / SBIGeM), in collaboration with SIMOPRO and Biomolecules Laboratory of the Sorbonne University's one, produced 200 cyclodipeptides containing non-natural amino acids by luring and diverting the cellular machinery for the synthesis of proteins. This unprecedented approach significantly increases the diversity of these bioactive molecules.

Transcription regulation by the Mediator: recent progress

Wed, 17 Jan 2018 11:00:00 GMT

Julie Soutourina (I2BC@Saclay / SBIGeM) was invited by Nature Reviews Molecular Cell Biology to publish a review on the molecular functioning of the Mediator, a multi-protein complex, conserved from yeast to humans, and essential to the regulation of the expression of genes. Potential therapeutic approaches targeting the Mediator (cancer, fungal infections) are also adressed.

Early and protective microglial activation in Alzheimer's Disease.

Thu, 17 Mar 2016 08:00:00 GMT

For the first time in human, a study proves that microglial activation seems to play a protective role in the clinical progression of the disease at these early stages of Alzheimer's disease.

Modulating cerebral cholesterol: a new avenue of research to treat Alzheimer’s disease?

Mon, 14 Sep 2015 10:00:00 GMT

Two French research teams have recently shown in a rodent model that overexpression of an enzyme capable of eliminating excess cholesterol in the brain can act in a beneficial way on the tau component of the disease to completely correct it.

How does a mobile DNA sequence find its target?

Fri, 01 May 2015 10:00:00 GMT

Certain mobile DNA sequences shape genomes and are maintained over the course of generations. How is this explained? The interaction between two proteins, which is essential for their integration into a specific area of the yeast genome, has been identified. This finding has interesting implications for gene therapy.

Bio-magnet for targeted medical imaging

Fri, 20 Feb 2015 11:00:00 GMT

The CEA-IBEB has partnered with the CEA-I2BM to develop original MRI contrast agents. Nano-magnets produced by bacteria may reveal targets at the molecular level.

Parkinson’s disease: a major breakthrough thanks to gene therapy

Fri, 10 Jan 2014 11:00:00 GMT

An Anglo-French team (AP-HP, Inserm, CEA/Mircen, UPEC, Oxford Biomedica, Cambridge University) coordinated by Professor Stéphane Palfi (head of the neurosurgery department at the hôpital Henri-Mondor) conducted a gene therapy trial in 15 patients with an advanced form of Parkinson’s disease.